Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis (UC) and Crohn’s disease (CD).
Related Articles
EUR/GBP gives away gains, retreats to 0.8250 on dovish ECB
The Euro has given away previous gains and is practically unchanged on...
The Fed decision looms. What are the technicals moving the market today?
The USD is little changed with the DXY index down marginally. THe...
Federal Reserve set for hawkish interest-rate cut as traders dial back chances of additional easing in 2025
The US Federal Reserve (Fed) will announce monetary policy decisions following the...
ForexLive European FX news wrap: Dollar steady awaiting the Fed
Headlines:AUD/USD extends downside run, eyes on the October 2023 lows nextECB's Wunsch:...
Leave a comment